If I relapse, is the previous treatment given again or should I consider a new therapy?

If I relapse, is the previous treatment given again or should I consider a new therapy? So the question is that if the disease comes back, should I go back to the treatment that worked before or should I really think about a new treatment? And your general thought would be, hey, something worked before, why not go back and try the same thing again? What worked before, why not now? But it depends on how quickly the disease comes back. Now, you know, if you have received traditional chemotherapy, be it a 3 plus 7 based kind of induction consolidation or chemotherapy based induction consolidation, now if the disease comes back after three, four years, then there's a very reasonable chance that would also respond to an intensive chemotherapy regimen. But on the other hand, if the disease comes back in about two, three months time, then there is a very small chance that you would respond to the same treatment. So the early relapses, mostly defined as within about a year, generally do not respond to the same treatment again. And that's where I think it's important to look at alternate options or a clinical trial option for this particular patient. But on the other hand, the patients who have late relapses, they can potentially still have chemo sensitive disease and you can potentially try the same chemotherapy or similar chemotherapy and take the patient to stem cell transplant. So it all depends on, mostly depends on the duration of response. And of course, you know, when the disease comes back, are they acquiring newer mutations? Some of the mutations, like if you acquire a B-52 mutation for that matter, the chances of your responding to chemotherapy is much lower. So possibly an alternate approach, maybe using a hypometallic agent would be a better approach than traditional chemotherapy. So it's an advanced answer, but in a way we're learning more about the disease with the new molecular studies that we do and we are realizing how the disease evolves and it's allowing us to also strategize in that way to how to address these questions.